This activity is supported by an unrestricted educational grant from Bristol-Myers Squibb, Genentech, Inc., and Merck & Co.
Non-Small Cell Lung Cancer: Immunotherapy
Suzanne Walker, CRNP, MSN, AOCN, BC
Abramson Cancer Center at Penn-Presbyterian Medical Center
Immunotherapy has made groundbreaking news across tumor types including an exciting emerging role in NSCLC. It is imperative for APs to understand this innovative approach in treating NSCLC. This activity provides an invaluable overview of the immune system, the role of checkpoint inhibitors, unique treatment considerations such as pseudo progression, immune mediated side effect profiles of these newer agents and management.
These CME/CE/CPE accredited activities are jointly provided by